29/03/2022 – AB Science acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading. Download PDF Post navigationPreviousPrevious post:Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsNextNext post:Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19Related PostsAnnual financial results as of 31 December, 2021April 29, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrantsFebruary 28, 2022AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsFebruary 24, 2022Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & NeuroinflammationFebruary 22, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022
Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrantsFebruary 28, 2022
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsFebruary 24, 2022
Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & NeuroinflammationFebruary 22, 2022
